Rising GLP1 drug demand strains manufacturing capacity, leaving medical device firms struggling to secure production for clinical trials and commercialization.
Medical device manufacturers are grappling with a severe shortage of production capacity as demand for GLP1 delivery devices surges. Big pharma’s push to scale GLP1 therapies has absorbed much of the available global manufacturing, leaving smaller firms and clinical-stage projects with limited options for small-batch production.